@article{CDT14520,
author = {Nathan D. Wong and Paul D. Rosenblit and Rosenblit Greenfield},
title = {Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond},
journal = {Cardiovascular Diagnosis and Therapy},
volume = {7},
number = {Suppl 1},
year = {2017},
keywords = {},
abstract = {In 2003, select families with familial hypercholesterolemia were first identified to have gain-of-function mutations for proprotein convertase subtilisin kexin type 9 (PCSK9) followed, in 2006, by the identification of those with lifelong low levels of LDL-C and lowered atherosclerotic cardiovascular disease (ASCVD) risk who had loss-of-function PCSK9 mutations. These discoveries led to the rapid development of PSCK9-targeted monoclonal antibody (PCSK9 mAb) therapies and, in 2015, 2 ‘fully-humanized’ PCSK9 mAbs (alirocumab and evolocumab) were marketed in the United States, Europe, and other countries. In a wide range of high risk patients, with and without ASCVD, these PCSK9 mAbs, as once or twice monthly subcutaneous injections, potently reduce LDL-C 50–65% beyond levels achieved by maximally tolerated statin therapy; approximately one-third of patients achieve LDL-C levels },
issn = {2223-3660}, url = {https://cdt.amegroups.org/article/view/14520}
}